Tag: Synaffix
Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies
Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
ADC Therapeutics Expands Agreement with Synaffix
The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...
Dutch Biotech Signs License Agreement with Chinese ADC Developer
The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...
First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...
The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology
The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...
Synaffix ADCs Significantly Expands the Therapeutic Index vs Cysteine-Engineered ADCs
Netherlands-bases biotechnology company Synaffix BV, which exclusively focuses on the development of novel antibody-drug conjugate (ADC) technology, confirmed that a new set of head-to-head...
New Key Patent Covers Synaffix’s Glycan-Conjugated ADC Development Process
Synaffix, a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms has received a new key patent for their...
Synaffix and ADC Therapeutics Sign Agreement for GlycoConnect™ and HydraSpace™ Technologies
Netherlands-based biotechnology company Synaffix has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary site-specific antibody-drug conjugate technologies. The company is exclusively focused...
